Abstract
Background: Cancer biomarkers (CBs) can be used in early detection of several cancers as well as in detection of recurrence and following response to treatment. We aimed to investigate the levels of CBs in proteinuric patients with primary glomerular disease (PGD) and diabetes mellitus, and compare them with healthy controls.
Methods: One hundred and two patients with untreated PGD, 62 proteinuric patients with diabetic nephropathy, and 84 healthy controls were enrolled. Levels of cancer antigen 125 (CA 125), cancer antigen 15–3 (CA 15–3), carcinoembriogenic antigen (CEA), α-fetoprotein (AFP), total prostate specific antigen (TPSA), free prostate specific antigen (FPSA) and carbohydrate antigen 19–9 (CA 19–9) were measured.
Results: Compared to healthy controls, levels of CA 125, CA 15–3 and CA 19–9 were higher in patients with PGD and diabetic patients (all p<0.05), while levels of TPSA, FPSA, AFP and CEA were lower (all p<0.05). There was no correlation between levels of cancer biomarkers and serum fibrinogen and serum amyloid A protein levels (all p>0.05). Both urinary protein excretion rate and serum albumin levels were correlated with all CBs (all p<0.05).
Conclusions: CBs levels seem to be changed in different proteinuric patients. This condition should be kept in mind when evaluating CBs levels in proteinuric patients.
References
1. Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA-125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000;15:1261–5.10.1093/humrep/15.6.1261Search in Google Scholar PubMed
2. Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos A, et al. Cancer antigen-125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150–4.10.1245/ASO.2003.05.015Search in Google Scholar PubMed
3. Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalma’s P, Szamosi S, et al. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 2008;31:372–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000261839400008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.jaut.2008.08.008Search in Google Scholar PubMed
4. Turner MD, Kleinman MS, Thayer W. Serum carcinoembryonic antigen (CEA) in patients with chronic inflammatory bowel disease. Digestion 1973;9:116–23.10.1159/000197437Search in Google Scholar PubMed
5. Szekanecz E, Sándor Z, Antal-Szalmás P, Soós L, Lakos G, Besenyei T, et al. Increased production of the soluble tumor-associated antigens CA19–9, CA125 and CA15–3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann NY Acad Sci 2007;1108: 359–71.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000249051600037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1196/annals.1422.037Search in Google Scholar PubMed
6. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007;39:859–63.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000249214000033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1007/s11255-006-9125-2Search in Google Scholar PubMed
7. Ghanny S, Ross C, Chan AK, Chan HH. Coagulopathy in a patient with nephrotic syndrome. Am J Hematol 2010;85: 708–10.10.1002/ajh.21782Search in Google Scholar PubMed
8. Villarreal IR, Ortega O, Gallar P, Sánchez M, Callejas R, Gracia C, et al. Clinical and biochemical characteristics of predialysis patients in terms of 25 hydroxy vitamin D levels. Nefrologia 2011;31:185–91.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000288844000011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
9. Ito S, Kano K, Ando T, Ichimura T. Thyroid function in children with nephrotic syndrome. Pediatr Nephrol 1994;8:412–5.10.1007/BF00856516Search in Google Scholar PubMed
10. Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, Mayer G. Serum tumor markers after renal transplantation. Transplantation 1996;62:1506–9.10.1097/00007890-199611270-00021Search in Google Scholar PubMed
11. Cases A, Filella X, Molina R, Ballesta A, Lopez-Pedret J, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183.10.1159/000186247Search in Google Scholar PubMed
12. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008;88:451–87.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000257595300005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1152/physrev.00055.2006Search in Google Scholar PubMed
13. Kaysen GA, Al Bander H. Metabolism of albumin and immunoglobulins in the nephrotic syndrome. Am J Nephrol 1990;10:36–42.10.1159/000168192Search in Google Scholar PubMed
14. Gao J, Cui J, Wang Y, Dong Z, Tian Y, Xu Y. Identification of potential predictors for subtype IgA nephropathy through analyses of blood biochemical indicators. Clin Chim Acta 2011;412:441–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000286713800006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
15. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007;8:1054–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000251762600009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/S1470-2045(07)70357-1Search in Google Scholar
16. Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19–9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci 2011;341:28–32.10.1097/MAJ.0b013e3181f0e2a0Search in Google Scholar PubMed
17. Joven J, Cliville X, Camps J, Espinel E, Simo J, Vilella E, et al. Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity. Clin Chem 1997;43:1223–31.10.1093/clinchem/43.7.1223Search in Google Scholar PubMed
18. Castellino P, Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clin Nutr Metab Care 2002;5:51–4.10.1097/00075197-200201000-00010Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
